COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis - Banerjee, Jineta; Friedman, Jan M.; Klesse, Laura J.; Yohay, Kaleb; Children’s Tumor Foundation Clinical Care Advisory Board; Jordan, Justin T; Plotkin, Scott; Allaway, Robert J; Blakeley, Jaishri (medRxiv, 2022)
Purpose People with pre-existing conditions may be more susceptible to severe Coronavirus disease 2019 (COVID-19) when infected by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The relative risk and severity of SARS-CoV-2 infection in people with rare diseases like neurofibromatosis (NF) type 1 (NF1), neurofibromatosis type 2 (NF2), or schwannomatosis (SWN) is unknown.Methods We investigated the proportions of SARS-CoV-2 positive or COVID-19 patients in people with NF1, NF2, or SWN in the National COVID Collaborative Cohort (N3C) electronic health record dataset.Results The cohort sizes in N3C were 2,501 (NF1), 665 (NF2), and 762 (SWN). We compared these to N3C cohorts of other rare disease patients (98 - 9844 individuals) and the general non-NF population of 5.6 million. The site- and age-adjusted proportion of people with NF1, NF2, or SWN who tested positive for SARS-CoV-2 or were COVID-19 patients (collectively termed positive cases) was not significantly higher than in individuals without NF or other selected rare diseases. There were no severe outcomes reported in the NF2 or SWN cohorts. The proportion of patients experiencing severe outcomes was no greater for people with NF1 than in cohorts with other rare diseases or the general population.Conclusion Having NF1, NF2, or SWN does not appear to increase the risk of being SARS-CoV-2 positive or of being a COVID-19 patient, or of developing severe complications from SARS-CoV-2.Competing Interest StatementJustin T Jordan is a recipient of royalties from Elsevier, and consulting fees from Navio Theragnostics, CereXis, and Recursion Inc. Scott Plotkin is co-founder of NFlection Therapeutics, NF2 Therapeutics; consults for Akouos; and serves on the Scientific Advisory Board and holds stock in SonALAsense.Funding StatementThis study was funded by the Neurofibromatosis Therapeutic Acceleration Program, and supported by the Clinical Care Advisory Board of Children’s Tumor Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Western Institutional Review Board - Copernicus Group (WCG) IRB of Sage Bionetworks gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data analyzed in this study are available online at the N3C Data Enclave (https://covid.cd2h.org/enclave). Access to data requires approval from the N3C data access committee. No new data was produced in this study. All the R code used for the analyses in this study is available on Github (https://github.com/jaybee84/NF-COVID-response). https://covid.cd2h.org/enclave